JP2025517355A - アトラセンタンを用いた巣状分節性糸球体硬化症の治療方法 - Google Patents

アトラセンタンを用いた巣状分節性糸球体硬化症の治療方法 Download PDF

Info

Publication number
JP2025517355A
JP2025517355A JP2024568249A JP2024568249A JP2025517355A JP 2025517355 A JP2025517355 A JP 2025517355A JP 2024568249 A JP2024568249 A JP 2024568249A JP 2024568249 A JP2024568249 A JP 2024568249A JP 2025517355 A JP2025517355 A JP 2025517355A
Authority
JP
Japan
Prior art keywords
subject
atrasentan
weeks
pharma
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024568249A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025517355A5 (enExample
Inventor
ジェームズ キング，アンドリュー
ワイ イップ トン，ヴィンセント
カマーゴ，マリアン
Original Assignee
チヌーク セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by チヌーク セラピューティクス，インコーポレイテッド filed Critical チヌーク セラピューティクス，インコーポレイテッド
Publication of JP2025517355A publication Critical patent/JP2025517355A/ja
Publication of JP2025517355A5 publication Critical patent/JP2025517355A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024568249A 2022-05-19 2023-05-18 アトラセンタンを用いた巣状分節性糸球体硬化症の治療方法 Pending JP2025517355A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263343574P 2022-05-19 2022-05-19
US63/343,574 2022-05-19
PCT/US2023/022681 WO2023225163A1 (en) 2022-05-19 2023-05-18 Methods of treating focal segmental glomerulosclerosis with atrasentan

Publications (2)

Publication Number Publication Date
JP2025517355A true JP2025517355A (ja) 2025-06-05
JP2025517355A5 JP2025517355A5 (enExample) 2026-05-11

Family

ID=88836135

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024568249A Pending JP2025517355A (ja) 2022-05-19 2023-05-18 アトラセンタンを用いた巣状分節性糸球体硬化症の治療方法

Country Status (10)

Country Link
US (1) US20250352511A1 (enExample)
EP (1) EP4525857A4 (enExample)
JP (1) JP2025517355A (enExample)
KR (1) KR20250013180A (enExample)
CN (1) CN119325377A (enExample)
AU (1) AU2023271840A1 (enExample)
CA (1) CA3252232A1 (enExample)
IL (1) IL316349A (enExample)
MX (1) MX2024013985A (enExample)
WO (1) WO2023225163A1 (enExample)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9255931B2 (en) * 2010-06-24 2016-02-09 Morehouse School Of Medicine Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
US20170014386A1 (en) * 2015-07-16 2017-01-19 Abbvie, Inc. Treatment of Multidrug-Resistant Nephrotic Syndrome (MDR-NS) in Children
CA3010593C (en) * 2016-01-05 2024-02-13 University Of Leicester Methods for inhibiting fibrosis in a subject in need thereof
IL294410B2 (en) * 2016-11-23 2024-02-01 Chemocentryx Inc A method for the treatment of focal segmental tuberous sclerosis
HRP20260121T1 (hr) * 2019-12-17 2026-03-13 Chinook Therapeutics, Inc. Farmaceutski prihvatljiva sol atrasentana za uporabu u postupku za liječenje iga nefropatije

Also Published As

Publication number Publication date
EP4525857A1 (en) 2025-03-26
AU2023271840A1 (en) 2024-10-31
EP4525857A4 (en) 2026-05-20
KR20250013180A (ko) 2025-01-31
IL316349A (en) 2024-12-01
MX2024013985A (es) 2025-02-10
US20250352511A1 (en) 2025-11-20
CA3252232A1 (en) 2023-11-23
CN119325377A (zh) 2025-01-17
WO2023225163A1 (en) 2023-11-23

Similar Documents

Publication Publication Date Title
JP7821870B2 (ja) アトラセンタンによるｉｇａ腎症を治療する方法
US20230270718A1 (en) Methods of treating diabetic kidney disease
US20250352511A1 (en) Methods of treating focal segmental glomerulosclerosis with atrasentan
US20220304979A1 (en) Methods of reducing disease flares
ES3062063T3 (en) A pharmaceutically acceptable salt of atrasentan for use in a method of treating iga nephropathy
HK40059453A (en) Methods of treating iga nephropathy with atrasentan
HK40094573A (en) Methods of treating iga nephropathy with atrasentan
BR122023026537A2 (pt) Uso de atrasentan para tratar nefropatia por iga
JP2025517355A5 (enExample)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260427